Alnylam wasn't the only biotech company to score on Wall Street after the announcement of its rich RNAi deal with Roche [1]. Isis Pharmaceuticals stands to gain $26.6 million along with milestones and royalties in the deal, and investors bid up its stock price by 17 percent. Isis licensed its RNAi tech to Alnylam in 2004. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/roche-harnesses-alnylam-s-rnai-tech-in-1b-deal/2007-07-09
[2] http://www.forbes.com/feeds/ap/2007/07/09/ap3896215.html